A retrospective study: Effects of additional SGLT2-inhibitor therapy on renal functions in patients with type 2 diabetes mellitus and stage 3b and 4 chronic kidney disease

A retrospective study: Effects of additional SGLT2-inhibitor therapy on renal functions in patients with type 2 diabetes mellitus and stage 3b and 4 chronic kidney disease - Renal benefits of SGLT2-inhibitors in advanced CKD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035278

Enrollment

Registered

2018-12-18

Start date

2018-04-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetes more than one year treatment history of SGLT2-inhibitors impaired renal function (15<eGFR<45) at beginning SGLT2-inhibitor therapy

Exclusion criteria

Exclusion criteria: type 1 DM cancer auto-immune disease active inflammation dimentia

Design outcomes

Primary

Measure	Time frame
improvement of annual changes in eGFR	—

Secondary

Measure	Time frame
improvement of urinary protein decrease in HbA1c	—

Countries

Japan

Contacts

Public ContactSeigo Sugiyama

Jinnouchi Hospital Diabetes Care Center

seigosugiyama@jinnouchi.or.jp096-363-0011

Outcome results